MENU
TNXP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

TNXP stock forecast, quote, news & analysis

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 20, 2026

Why Tonix Pharmaceuticals (TNXP) Stock Is Down 55% in the Last 30 Days

Key Takeaways

  • TNXP shares have declined roughly 55% over the past 30 days, falling from about $5.43 to the low $2 range and touching a 52-week low.
  • Third-quarter revenue jumped 424% year over year to $17.2 million, led by $15 million in TONMYA net sales (up 37% quarter over quarter), but the bottom line missed expectations.
  • The Q3 net loss widened to $53.3 million from $32.0 million a year earlier, and the company's cash is only expected to fund operations into early Q3 2027.
  • Rising share counts, continued capital needs, and a patent challenge from Dr. Reddy's Laboratories (RDY) on TONMYA are key overhangs weighing on sentiment.
  • For more detail on valuation, financials, and outlook, explore TNXP's Price Targets, Earnings, and Forecast pages.
  • Explore Trending AI Robots to see how AI-driven trading bots are positioning across the market.

Tonix Pharmaceuticals (TNXP) Company Overview and Market Position

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments for conditions with high unmet medical need. Its flagship product is TONMYA, a non-opioid, sublingual form of cyclobenzaprine that received FDA approval as the first new fibromyalgia treatment in more than 15 years. The company also markets two acute migraine products, Zembrace SymTouch and Tosymra, and is advancing a pipeline that includes TNX-102 SL for major depressive disorder, the TNX-4800 antibody for Lyme disease prevention, and TNX-1500 for kidney transplant rejection prevention.

Investors follow TNXP primarily for the commercial ramp of TONMYA, which launched in November 2025, and for the progress of its clinical-stage programs. As a small-cap biotech with a growing but still-early product franchise, the company's valuation is closely tied to launch execution, payer coverage, cash runway, and pipeline milestones.

Tonix Pharmaceuticals (TNXP) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, TNXP shares have fallen sharply. From a closing price of about $5.43 roughly 30 days earlier, the stock declined to roughly $2.42, a drop of approximately 55%. The move has been persistent rather than a single-session shock, with the shares grinding lower through late October and November and setting repeated 52-week lows.

The quarterly picture is even steeper. Roughly three months ago, the stock traded near $12.40; against the latest price of about $2.42, that represents a decline of roughly 80%. The shares are down about 84% over the trailing 52 weeks, and short interest remains elevated at roughly 17% of the float, underscoring the negative sentiment that has built up around the name.

What Drove TNXP Stock Price in the Last 30 Days

The dominant catalyst in the last 30 days was the company's third-quarter earnings report on November 9. Tonix delivered strong top-line momentum — net product revenue of $17.2 million beat consensus and TONMYA net sales rose 37% quarter over quarter — but the profit line disappointed. GAAP EPS came in at a loss of $2.89 per share, worse than the roughly $2.39-to-$2.43 loss analysts had modeled, and the net loss widened to $53.3 million as R&D and selling costs climbed.

Investors focused less on the revenue beat and more on the financial trajectory. Management said cash and cash equivalents of approximately $163 million, together with about $1.5 million in subsequent equity proceeds, are expected to fund operations only into early Q3 2027 — a runway of less than 12 months. That, combined with a share count that has grown roughly 148% over the past year, has intensified concerns about future dilution. Around the same period, Alliance Global Partners lowered its price target to $40 from $65, citing anticipated share-count growth through 2027.

Separately, a patent dispute added uncertainty. Dr. Reddy's Laboratories filed an abbreviated new drug application with a Paragraph IV certification challenging TONMYA's patents, and Tonix responded by filing a patent infringement complaint, which triggered a statutory stay. The litigation introduces both cost and competitive risk to the company's core asset.

What Drove TNXP Stock Performance Over the Last Quarter

The longer-term decline reflects a broader repricing of the equity rather than a single negative event. Even as TONMYA's launch gained traction — total prescriptions rose 28% quarter over quarter to 16,375, and payer coverage expanded to roughly 166 million covered lives — the company has continued to spend heavily on commercialization and pipeline development, producing large and widening net losses.

Over the quarter, the market has increasingly valued the stock on its cash burn, financing requirements, and dilution risk rather than on the revenue ramp alone. The shares now trade at a market capitalization well below the company's cash balance, a signal that investors are pricing in the anticipated capital raises and the near-term uncertainty around profitability and the TONMYA patent challenge. Broader weakness in small-cap biotech has compounded the pressure on the name.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated look at AI-powered trading bots that scan thousands of tickers across the market. While Tickeron hosts hundreds of bots spanning a wide range of strategies, timeframes, and performance metrics, only the top-performing and most relevant bots are featured in this section. Each bot follows a distinct approach, so traders can review parameters such as strategy type, holding period, and historical results to find models that fit their own style. For investors monitoring volatile names like TNXP, the page provides a way to see how automated, data-driven strategies are positioning across the broader market.

TNXP Stock Forecast Drivers: What Investors Should Watch Next

Going forward, investors are likely to focus on several factors. First, TONMYA prescription and revenue trends will remain the core fundamental gauge, particularly as expanded payer coverage and a larger sales force work through to net sales. Second, the company's cash position and any new financing activity will be closely watched, given the runway guidance into early Q3 2027 and the elevated share count. Third, the outcome and progress of the patent litigation with Dr. Reddy's Laboratories will shape confidence in TONMYA's exclusivity.

On the pipeline side, key milestones include continued enrollment in the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned initiation of the TNX-4800 Lyme disease field study, and the investigator-initiated TNX-1500 kidney transplant study — with several programs expected to advance in early 2027. These catalysts carry both upside potential and execution risk, and none of this information constitutes financial advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for TNXP with price predictions
Nov 20, 2026

TNXP sees MACD Histogram just turned negative

TNXP saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 31 instances where the indicator turned negative. In 31 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TNXP entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in 180 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.596). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company which engages in developing and manufacturing pharmaceuticals

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
200 Connell Drive
Phone
+1 862 799-8599
Employees
142
Web
https://www.tonixpharma.com
Why Tonix Pharmaceuticals (TNXP) Stock Is Down 55% in the Last 30 Days